Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer

被引：0
|
作者：
Kathleen Moore
John K. Chan
Angeles Alvarez Secord
Manish R. Patel
Timothy Callahan
Wei Guo
Zhi-Yi Zhang
机构：
[1] University of Oklahoma HSC,Stephenson Cancer Center
[2] Sarah Cannon Research Institute,Palo Alto Medical Foundation, California Pacific Medical Center
[3] Sutter Health Sutter West Bay,undefined
[4] Duke Cancer Institute,undefined
[5] Florida Cancer Specialists and Research Institute,undefined
[6] BioTel Research,undefined
[7] TESARO,undefined
[8] Inc,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 83卷
关键词：
Niraparib; PARP inhibitor; Cardiac repolarization; QTc interval; Ovarian cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：717 / 726
页数：9
相关论文
共 50 条
  • [21] Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: An updated series
    Shih, K. K.
    Chi, D. S.
    Barakat, R. R.
    Leitao, M. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2010, 117 (02) : 330 - 335
  • [22] Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An updated series
    Shih, K. K.
    Chi, D. S.
    Barakat, R. R.
    Leitao, M. M.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S155 - S155
  • [23] Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer
    Webber, Kate
    Friedlander, Michael
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 41 : 126 - 138
  • [24] OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    Aghajanian, Carol
    Blank, Stephanie V.
    Goff, Barbara A.
    Judson, Patricia L.
    Teneriello, Michael G.
    Husain, Amreen
    Sovak, Mika A.
    Yi, Jing
    Nycum, Lawrence R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2039 - 2045
  • [25] Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer
    Rimel, B. J.
    Dockery, Lauren
    Randall, Leslie M.
    Moore, Kathleen
    FUTURE ONCOLOGY, 2020, 16 (33) : 2701 - 2711
  • [26] Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
    Zhong, Lixian
    Anh Thu Tran
    Tomasino, Taylor
    Nugent, Elizabeth
    Smith, Judith A.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (12): : 1219 - 1228
  • [27] Real-Life Data of Niraparib Maintenance Treatment in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 10 - 11
  • [28] Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer
    Teneriello, M. G.
    Tseng, P. C.
    Crozier, M.
    Encarnacion, C.
    Hancock, K.
    Messing, M. J.
    Boehm, K. A.
    Williams, A.
    Ilegbodu, D.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] EFFECTIVENESS OF ORAL ETOPOSIDE IN RECURRENT OR REFRACTORY EPITHELIAL OVARIAN CANCER, PRIMARY PERITONEAL CANCER AND FALLOPIAN TUBE CANCER
    Kongsawatvorakul, C.
    Charakorn, C.
    Chittithaworn, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 742 - 742
  • [30] Cost-effectiveness analysis of niraparib maintenance therapy in Chinese patients with platinum-sensitive recurrent ovarian cancer
    Qiu, Yijin
    Zha, Jingkai
    Ma, Aixia
    Zhou, Ting
    GYNECOLOGIC ONCOLOGY, 2023, 174 : 175 - 181
12345